Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents – United States, 2021-2023
This study assesses the durability of the original monovalent mRNA COVID-19 vaccine in preventing hospitalization due to the Omicron variant among U.S. children aged 5-18. Between December 2021 and October 2023, vaccine effectiveness (VE) was 52% within 120 days of the last dose but dropped to 19% for doses received 120-364 days prior. VE was 31% when the last dose was within the past year. For severe cases requiring intensive interventions, VE was higher shortly after vaccination but decreased over time. The study supports CDC recommendations for updated vaccinations in children and adolescents.